Basic Information
| LncRNA/CircRNA Name | LINC00675 |
| Synonyms | NORAD, LINC00657, ASHGA5P032173 |
| Region | GRCh38_20:36045622-36050960 |
| Ensemble | ENSG00000260032 |
| Refseq | NR_027451 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Western blot, RIP |
| Sample | cell lines ( A498 and 786-O cells) |
| Expression Pattern | down-regulated |
| Function Description | lncRNA LINC00675 whose expression was significantly decreased in GC tissues compared with the adjacent non-tumor tissues, and its low expression was associated with the poor survival of GC patients. LINC00675 was a tumor suppressor because it repressed the proliferation, migration and invasion of GC cells in-vitro and also inhibited the distal pulmonary and hepatic metastases of GC cells in-vivo.LINC00675 interacted with vimentin, a protein involved in cell metastasis, and enhanced its phosphorylation level on Ser83 to result in the collapse of vimentin filament in GC cells, thereby reducing cell metastasis. LINC00675 expression signature may serve as a novel biomarker for the diagnosis and prognosis of GC,and also highlight that LINC00675/vimentin complex may be a potentially therapeutic target of GC. |
| Pubmed ID | 29107103 |
| Year | 2018 |
| Title | Long noncoding RNA LINC00675 enhances phosphorylation of vimentin on Ser83 to suppress gastric cancer progression. |
External Links
| Links for LINC00675 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |